---
created: 2025-04-13
updated: 2025-04-13T10:53
id: v0xvfMu-6Z
specialty: immuno
specialty_id: 124
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::pembrolizumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::pembrolizumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::cancer-immunotherapy
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Pembrolizumab is indicated for the treatment of **all solid tumors** that bear a(n) **PD-L1** mutation

---

# Answer
Pembrolizumab binds to the PD1 receptor on T cells, preventing aberrant PD-L1 expression from stimulating it